. 2020 Dec 10;32(5):817–829. doi: 10.1007/s00198-020-05756-8

Table 1.

Criteria for aBMD assessment or vertebral fracture risk assessment in China

aBMD measurement	Vertebral fracture assessment
(1) over 65 (women) or 70 (men) years of age, (2) < 65 (women) or < 70 (men) years with one or more major risk factors for osteoporosis: •Fragility fracture •Hypogonadism •Radiograph with the manifestation of osteoporosis •Receive osteoporosis pharmacotherapy •Diagnosis of disease influencing bone metabolism •IOF 1-min questionnaire with “+” indicated for questions requiring “greater than” responses •OSTA score ≤ − 1	(1) Women ≥ 70 years and men ≥ 80 years with an aBMD T-score ≤ − 1 (2) Women 65–69 years, and men 70–80 years with an aBMD T ≤ − 1.5 (3) Adults (≥ 50 years) with one of the following: a Fragility fracture b Height decrease of ≥ 4 cm, as compared to peak adult height c Height decrease of ≥ 1 cm within 1 year d Glucocorticoid therapy ≥ 3 months

aBMD measurement

Vertebral fracture assessment

(1) over 65 (women) or 70 (men) years of age,

(2) < 65 (women) or < 70 (men) years with one or more major risk factors for osteoporosis:

•Fragility fracture

•Hypogonadism

•Radiograph with the manifestation of osteoporosis

•Receive osteoporosis pharmacotherapy

•Diagnosis of disease influencing bone metabolism

•IOF 1-min questionnaire with “+” indicated for questions requiring “greater than” responses

•OSTA score ≤ − 1

(1) Women ≥ 70 years and men ≥ 80 years with an aBMD T-score ≤ − 1

(2) Women 65–69 years, and men 70–80 years with an aBMD T ≤ − 1.5

(3) Adults (≥ 50 years) with one of the following:

a Fragility fracture

b Height decrease of ≥ 4 cm, as compared to peak adult height

c Height decrease of ≥ 1 cm within 1 year

d Glucocorticoid therapy ≥ 3 months

aBMD, bone mineral density; IOF, International Osteoporosis Foundation; OSTA, Osteoporosis Self-Assessment Tool for Asians